1. Диагностика и лечение хронической сердечной недостаточности. Рекомендации ВНОК. III пересмотр. Сердечная недостаточность. 2010; 1: 69–160.
2. Ahmed A, Husain A, Love TE et al. Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods. Eur Heart J 2006; 27 (12): 1431–9.
3. Akcicek F, Yalniz T, Basci A et al. Diuretic effect of frusemide in patients with nephrotic syndrome: is it potentiated by intravenous albumin? BMJ 1995; 310 (6973): 162–3.
4. Bellomo R, Ronco C, Kellum JA et al. Acute renal failure – definition, outcome measures, animal models, fluid therapy and information technology needs. The second international consensus conference of Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004; 8: R204–R212.
5. Chalasani N, Gorski JC, Horlander JC et al. Effects of albumin/furosemide mixtures on responses to furosemide in hypoalbuminemic patients. J Am Soc Nephrol 2001; 12: 1010–6.
6. KDOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease 2002.
7. Pitt B, Remme W, Zannad F et al. for the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309–21.
8. Yilmaz MB, Gayat E, Salem R et al. Impact of diuretic dosing on mortality in acute heart failure using a propensity-matched analysis. Eur J Heart Fail 2011; 13 (11): 1244–52.
Авторы
М.М.Батюшин, А.А.Кастанаян, Б.И.Воробьев
ГБОУ ВПО Ростовский государственный медицинский университет Минздрава РФ